Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
NCT03953456 · Genfit · PHASE2 · terminated · last registry update 2020-08-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Continuation of the trial cannot serve a scientific purpose” | – | Registry record, Genfit |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-10Phase 3 first posted: Kowa Company, Ltd., K-877 0.1 mg tablet + Fenofibrate 200 mg capsule (NCT04998981)
- 2021-05-11Phase 3 first posted: Laboratorios Silanes S.A. de C.V., Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose + Atorvastatin (Lipitor ®) (NCT04882293)
- 2021-03-19Phase 3 first posted: Chipscreen Biosciences, Ltd., Chiglitazar 32mg + Chiglitazar 48mg (NCT04807348)
- 2021-02-12Phase 3 first posted: Instituto Mexicano del Seguro Social, Bezafibrate 200 MG Oral Tablet + Placebo (NCT04751188)
- 2021-01-20Phase 3 first posted: Kowa Company, Ltd., K-877 ER 0.2 mg/day morning administration (once daily) + K-877 ER 0.2 mg/day evening administration (once daily) (NCT04716595)
- 2021-01-19Phase 3 first posted: Kowa Company, Ltd., K-877 ER 0.2 mg/day (once daily) + K-877 ER 0.4 mg/day (once daily) (NCT04714151)
- 2020-12-29Results posted on the registry: Sanofi, Alirocumab SAR236553 (REGN727) + Atorvastatin (NCT03510715)
- 2020-12-17Results posted on the registry: Gilead Sciences, Firsocostat + Fenofibrate (NCT02891408)
- 2020-12-10Phase 3 first posted: Jaeb Center for Health Research, Fenofibrate (NCT04661358)
- 2020-12-10Phase 3 first posted: Yaakov Nahmias, TriCor® 145mg tablets (NCT04661930)
- 2020-11-19Phase 3 first posted: Polaryx Therapeutics, Inc., PLX-200 + Placebo (NCT04637282)
- 2020-09-23Phase 3 first posted: Hôpital Necker-Enfants Malades, Béfizal (NCT04561466)
- 2020-09-16Results posted on the registry: Jaeb Center for Health Research, Pemafibrate + Placebo (NCT03345901)
- 2020-09-16Also stopped (terminated): Jaeb Center for Health Research, Pemafibrate + Placebo (NCT03345901)
- 2020-08-26Phase 3 first posted: Ipsen, Elafibranor 80mg + Placebo (NCT04526665)
- 2020-03-24Results posted on the registry: Asahi Kasei Therapeutics, Inc., LCP-AtorFen (NCT00664859)
- 2020-03-16Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy + Placebo of Bezafibrate in addition to standard UDCA therapy (NCT04309773)
- 2020-02-05Results posted on the registry: Asahi Kasei Therapeutics, Inc., LCP-AtorFen + atorvastatin (NCT00504829)
- 2019-12-11Phase 3 first posted: Asian Institute of Gastroenterology, India, Saroglitazar + Vitamin E (NCT04193982)
- 2019-11-29Also stopped (terminated): The University of Texas Medical Branch, Galveston, Fenofibrate + Placebo (NCT02452255)
- 2019-11-29Also stopped (terminated): The University of Texas Medical Branch, Galveston, Fenofibrate + Sugar Pill (NCT01574131)
- 2019-09-24Results posted on the registry: Genfit, Elafibranor 80 mg + Elafibranor 120 mg (NCT03124108)
- 2019-09-09Results posted on the registry: Sanofi, Alirocumab SAR236553 + Atorvastatin (NCT02984982)
- 2019-09-06Results posted on the registry: Sanofi, alirocumab SAR236553 (REGN727) + statins (NCT02890992)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision